Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at B. Riley

Key Points

• Analysts at B. Riley have initiated coverage of Actuate Therapeutics (NASDAQ:ACTU) with a "buy" rating, while other analysts have varied opinions, including a "sell" rating from Wall Street Zen.
• Actuate Therapeutics' shares have shown a price increase of 2.6%, currently priced at $8.19, compared to a twelve-month high of $11.99.
• Insider transactions reveal significant buying activity, with directors purchasing a total of 214,284 shares during the last three months, reflecting strong insider confidence in the company.

Analysts at B. Riley began coverage on shares of Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) in a research report issued on Monday, August 25th, MarketBeat reports. The firm set a "buy" rating and a $20.00 price target on the stock. B. Riley's price objective suggests a potential upside of 136.97% from the stock's current price. B. Riley also issued estimates for Actuate Therapeutics' Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($1.27) EPS, FY2028 earnings at ($0.83) EPS and FY2029 earnings at $0.01 EPS.

Other analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Actuate Therapeutics in a research note on Monday, August 18th. Wall Street Zen cut shares of Actuate Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $20.33.

Actuate Therapeutics Stock Up 2.7%

ACTU stock traded up $0.22 during midday trading on Monday, hitting $8.44. The stock had a trading volume of 41,064 shares, compared to its average volume of 55,102. Actuate Therapeutics has a 12-month low of $5.47 and a 12-month high of $11.99. The company's 50-day moving average price is $7.12 and its 200 day moving average price is $7.92.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.11).

Insider Activity

In other Actuate Therapeutics news, Director Aaron G.L. Fletcher bought 71,428 shares of Actuate Therapeutics stock in a transaction that occurred on Friday, June 27th. The shares were acquired at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the acquisition, the director owned 196,428 shares of the company's stock, valued at $1,374,996. The trade was a 57.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Equity Cof Lp Bios bought 71,428 shares of Actuate Therapeutics stock in a transaction that occurred on Friday, June 27th. The shares were acquired at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the acquisition, the director directly owned 196,428 shares in the company, valued at approximately $1,374,996. This represents a 57.14% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 214,284 shares of company stock valued at $1,499,988 in the last ninety days. Company insiders own 69.34% of the company's stock.

Hedge Funds Weigh In On Actuate Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Chicago Partners Investment Group LLC acquired a new position in shares of Actuate Therapeutics during the 1st quarter valued at $70,000. Sfmg LLC acquired a new position in shares of Actuate Therapeutics during the 1st quarter valued at $74,000. Envestnet Asset Management Inc. acquired a new position in shares of Actuate Therapeutics during the 4th quarter valued at $83,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Actuate Therapeutics during the 4th quarter valued at $84,000. Finally, Bank of America Corp DE lifted its holdings in shares of Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company's stock valued at $93,000 after acquiring an additional 15,267 shares in the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.